iwCLL 2019 | MRD assessment and the treatment of patients in the ‘real world’
Arnon Kater, Barbara Eichhorst and Thomas Kipps
• 20 Sep 2019
Thomas Kipps, MD, PhD, from University of California San Diego, San Diego, CA, Barbara Eichhorst, MD, from University Hospital Cologne, Cologne, Germany, and Arnon Kater, MD, PhD, from the University of Amsterdam, Amsterdam, The Netherlands, discuss the highlights of the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. The speakers discuss the importance of measurable residual disease (MRD) assessment and what it means for clinical outcome. The use of MRD and genetic testing in the clinical setting is also discussed.
